Skip to content
DataLookout
Menu

NCT06831526

Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma

StatusSuspended
PhaseEarly Phase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗

  1. Stopped Recruitment suspended Sponsor's reason: Drugs/Equipment Unavailable
    • Eligibility criteria expanded, about 29 words
    • Site details revised
  2. Minor Site contact updatedv7
  3. Notable Trial status: Not Yet Recruiting to Recruitingv6 Show 4 more changesShow less
    • Primary completion date: Jan 31, 2029 to Feb 28, 2029
    • Study completion date: Jul 31, 2030 to Aug 31, 2030
    • Start date changed from estimate of Oct 31, 2025 to Nov 6, 2025
    • Site details revised
  4. Notable Start date: Sep 30, 2025 to Oct 31, 2025
    • Primary completion date: Dec 31, 2028 to Jan 31, 2029
    • Study completion date: Jun 30, 2030 to Jul 31, 2030
    v5
  5. Notable Start date: Jul 31, 2025 to Sep 30, 2025
    • Primary completion date: Oct 31, 2028 to Dec 31, 2028
    • Study completion date: Apr 30, 2030 to Jun 30, 2030
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Notable Eligibility criteria expanded, about 15 wordsv3
  2. Notable Primary completion date: Oct 31, 2027 to Oct 31, 2028v2 Show 4 more changesShow less
    • Start date: May 31, 2025 to Jul 31, 2025
    • Eligibility criteria expanded, about 9 words
    • Study completion date: May 31, 2029 to Apr 30, 2030
    • Secondary endpoints revised (5)
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Percentage of immune-suppressive myeloid cells in the tumor tissue
Timeframe: At time of surgery or LITT (estimated to be day 60)
Percentage of immune-suppressive T cells in the tumor tissue
Timeframe: At time of surgery or LITT (estimated to be day 60)

Secondary (5)

Number of participants with adverse events
Number of participants with intolerable toxicities
Progression-free survival (PFS)
Overall survival (OS)
Feasibility of the regimen as measured by the number of participants who proceed with post-chemoradiotherapy surgery or LITT

Arms and interventions

Arm 1: Neoadjuvant RT and Temozolomide (TMZ) + Surgery or LITT + Adjuvant TMZ & AzeliragonActive comparator

Radiation therapy (RT) will consist of fractionated RT to 60 Gy in 30 daily fractions administered per standard of care RTOG approach. Concurrent TMZ during RT will be self-administered by mouth (PO) as per standard of care. 1 month after completion of RT, patient will proceed with planned surgery of either resection or LITT. Patients will then receive adjuvant TMZ and azeliragon for up to 6 months. Patient should start with the loading dose 30 mg BID for 6 days before the start of adjuvant TMZ. After 6 days, azeliragon 20 mg once daily should be continued in combination with TMZ.

Arm 2: Neoadjuvant RT, Temozolomide (TMZ) & Azeliragon + Surgery or LITT + Adjuvant TMZ & AzeliragonExperimental

RT will consist of fractionated RT to 60 Gy in 30 daily fractions administered per standard of care RTOG approach. Concurrent TMZ during RT will be self-administered by mouth (PO) as per standard of care. Patients will receive azeliragon as well. Azeliragon is self-administered PO. Azeliragon dosing will consist of 6 days of a loading dose of 30 mg twice per day starting on day -6, followed by 20 mg daily starting on the Day 1. Concurrent RT and TMZ start on Day 1. Azeliragon should continue until the day before planned surgical procedure. 1 month after completion of RT, patient will proceed with planned surgery of either resection or LITT. Patients will then receive adjuvant TMZ and azeliragon for up to 6 months. Patient should start with the loading dose 30 mg BID for 6 days before the start of adjuvant TMZ. After 6 days, azeliragon 20 mg once daily should be continued in combination with TMZ.

Drugs: Azeliragon, Temozolomide

Radiation: Radiation therapy

Procedures: Surgery or LITT

Sites

1 site in 1 country

  • Washington University School of MedicineSt Louis, Missouri, United States